MENU
+Compare
IGC
Stock ticker: ASE
AS OF
Jan 14 closing price
Price
$0.33
Change
-$0.01 (-2.94%)
Capitalization
25.26M

IGC IGC Pharma Forecast, Technical & Fundamental Analysis

a company, which engages in focuses on developing and commercializing a portfolio of cannabinoid based biopharmaceutical therapies

Industry Biotechnology
IGC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for IGC with price predictions
Jan 08, 2025

IGC's Stochastic Oscillator dives into oversold zone

The Stochastic Oscillator for IGC moved into oversold territory on January 08, 2025. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IGC advanced for three days, in of 215 cases, the price rose further within the following month. The odds of a continued upward trend are .

IGC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 76 cases where IGC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for IGC moved out of overbought territory on December 16, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on December 24, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on IGC as a result. In of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for IGC turned negative on December 24, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at .

IGC moved below its 50-day moving average on December 23, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for IGC crossed bearishly below the 50-day moving average on December 26, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 22 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IGC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.423) is normal, around the industry mean (15.212). P/E Ratio (0.000) is within average values for comparable stocks, (87.972). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.839). IGC has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (19.084) is also within normal values, averaging (258.672).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IGC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IGC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
IGC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

IGC is expected to report earnings to rise 50.00% to -2 cents per share on February 12

IGC Pharma IGC Stock Earnings Reports
Q4'24
Est.
$-0.03
Q3'24
Beat
by $0.01
Q2'24
Beat
by $0.01
Q1'24
Est.
$-0.04
Q4'23
Missed
by $0.05
The last earnings report on November 14 showed earnings per share of -1 cents, beating the estimate of -2 cents. With 416.82K shares outstanding, the current market capitalization sits at 25.26M.
A.I. Advisor
published General Information

General Information

a company, which engages in focuses on developing and commercializing a portfolio of cannabinoid based biopharmaceutical therapies

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
10224 Falls Road
Phone
+1 301 983-0998
Employees
61
Web
https://www.igcinc.us
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TTWO180.031.27
+0.71%
Take-Two Interactive Software
ORA66.10-0.37
-0.56%
Ormat Technologies
AZUL2.01-0.03
-1.47%
Azul SA
BCYC14.81-0.35
-2.31%
Bicycle Therapeutics plc
KOSS6.69-0.35
-4.97%
Koss Corp

IGC and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, IGC has been loosely correlated with TECX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if IGC jumps, then TECX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IGC
1D Price
Change %
IGC100%
-2.80%
TECX - IGC
37%
Loosely correlated
+0.45%
ANVS - IGC
30%
Poorly correlated
-2.10%
AMLX - IGC
30%
Poorly correlated
-1.57%
VNDA - IGC
27%
Poorly correlated
-3.31%
VTGN - IGC
27%
Poorly correlated
-3.07%
More